Athersys (ATHX) Stock Declines 19% Amid Biotech Rout
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
Tweet
Share
E-mailGet Alerts ATHX Hot Sheet
Join SI Premium – FREE
Athersys, Inc. (Nasdaq: ATHX) declined 19% on Monday. Athersys is a clinical-stage biotechnology company that develops stem cell products for treating immune disorders. Neuralstem, Inc. (NYSE: CUR) and StemCells Inc. (Nasdaq: STEM) also declined.
Broadly, biotech stocks sold off on Monday, with iShares Nasdaq Biotechnology ETF (Nasdaq: IBB) lower by 3.5%. ProShares Ultra Nasdaq Biotechnology (Nasdaq: BIB) saw heavy volume.
Broadly, biotech stocks sold off on Monday, with iShares Nasdaq Biotechnology ETF (Nasdaq: IBB) lower by 3.5%. ProShares Ultra Nasdaq Biotechnology (Nasdaq: BIB) saw heavy volume.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic To Have Over 3.5Gw Computing Power By End 2026 - NYT
- Trump: Iran wants a settlement, as soon as possible. It could happen
- Narragansett Bancorp opens at $10.80, above IPO at $10
Create E-mail Alert Related Categories
ETFs, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
